Seeking Alpha

Eli Lilly (LLY -0.4%) is halting the Phase III trial of its tabalumab drug in patients with...

Eli Lilly (LLY -0.4%) is halting the Phase III trial of its tabalumab drug in patients with rheumatoid arthritis, due to insufficient efficacy. However, Lilly will continue two other Phase III studies, which are testing tabalumab for systemic lupus erythematosus, an autoimmune disease. Tabalumab's failure adds to that for AsraZeneca's fostamatinib, and follows a blow for Lilly's solanezumab treatment for Alzheimer's. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|